Top

American Journal of Clinical Dermatology

Published in:

01-02-2013 | Adis Drug Clinical Q&A

Vismodegib

A Guide to its Use in Locally Advanced or Metastatic Basal Cell Carcinoma

Authors: Katherine A. Lyseng-Williamson, Gillian M. Keating

Published in: American Journal of Clinical Dermatology | Issue 1/2013

Abstract

Vismodegib is the first Hedgehog pathway inhibitor to be approved in the USA, where it is indicated for the treatment of adults with metastatic basal cell carcinoma (BCC), or with locally advanced BCC that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation. In an ongoing, noncomparative, phase II trial, oral vismodegib was effective in and had an acceptable tolerability profile in the treatment of patients with locally advanced or metastatic BCC.

National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines^®): basal cell and squamous cell skin cancers (version 2.2012). Fort Washington (PA): National Comprehensive Cancer Network, Inc.; 2012.

Weinstock MA, Still JM. Assessing current treatment options for patients with severe/advanced basal cell carcinoma. Semin Cutan Med Surg. 2011;30(4 Suppl):S10–3.PubMedCrossRef

Harris LG, Samant RS, Shevde LA. Hedgehog signaling: networking to nurture a promalignant tumor microenvironment. Mol Cancer Res. 2011;9(9):1165–74.PubMedCrossRef

LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17(8):2502–11.PubMedCrossRef

Erivedge™ (vismodegib) capsule for oral use: US prescribing information. South San Francisco (CA): Genentech, Inc.; 2012 Jan.

Robarge KD, Brunton SA, Castanedo GM, et al. GDC-0449: a potent inhibitor of the hedgehog pathway. Bioorg Med Chem Lett. 2009;19(19):5576–81.PubMedCrossRef

Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361(12):1164–72.CrossRef

Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171–9.PubMedCrossRef

Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of the Hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma (BCC): ERIVANCE BCC study update [abstract no. 8579]. 48th Annual Meeting of the American Society of Clinical Oncology; 2012 Jun 1–5; Chicago.

10.

Keating GM. Vismodegib in locally advanced or metastatic basal cell carcinoma. Drugs. 2012;72(11):1535–41.PubMedCrossRef

Title: Vismodegib
A Guide to its Use in Locally Advanced or Metastatic Basal Cell Carcinoma
Authors: Katherine A. Lyseng-Williamson
Gillian M. Keating
Publication date: 01-02-2013
Publisher: Springer International Publishing AG
Published in: American Journal of Clinical Dermatology / Issue 1/2013
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI: https://doi.org/10.1007/s40257-012-0004-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Vismodegib

A Guide to its Use in Locally Advanced or Metastatic Basal Cell Carcinoma

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Principal Determinants of the Length of Remission of Psoriasis Vulgaris After Topical, NB-UVB, and PUVA Therapy

Risk of Cardiovascular Disorders in Psoriasis Patients

Depigmentation Patterns of Nonsegmental Vitiligo

Vemurafenib

Combination Therapy in Psoriasis

Diagnosis and Treatment of Lichen Sclerosus